ABT-263

Product ID A0777

Cas No. 923564-51-6

Purity ≥99%

Unit Size	Cost	Quantity		Stock

Bulk Quote

Add to Wishlist

Quicklinks

Description
Product Info
Shipping and Storage
Downloads
References

Description
Product Info
Shipping and Storage
Downloads
References
Custom Order

Description

ABT-263 is a BH3 mimetic that inhibits Bcl-2, Bcl-ω, and Bcl-xl. ABT-263’s inhibition of Bcl-xl results in thrombocytopenia by inducing apoptotic death of platelets, limiting its usage. ABT-263 exhibits anticancer chemotherapeutic activity and shows some benefit in clinical trials. In chronic lymphocytic leukemia (CLL) cells, ABT-263 inhibits cell proliferation. In cellular and animal models of cancers with solid tumors, ABT-263 enhances the chemotherapeutic activity of several co-administered treatments.

Product Info

Cas No.	923564-51-6
Purity	≥99%
Formula	C₄₇H₅₅ClF₃N₅O₆S₃
Formula Wt.	974.61
IUPAC Name	4-[4-[[2-(4-chlorophenyl)-5,5-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[4-[[(2R)-4-morpholin-4-yl-1-phenylsulfanylbutan-2-yl]amino]-3-(trifluoromethylsulfonyl)phenyl]sulfonylbenzamide
Synonym	Navitoclax, A-855071
Solubility	DMSO 100 mg/mL (102.6 mM) Water Insoluble Ethanol Insoluble
Appearance	White to off white powder

Shipping and Storage

Store Temp	4°C
Ship Temp	Ambient

Downloads

MSDS	A0777 MSDS PDF
Info Sheet	A0777 Info Sheet PDF

References

Debrincat MA, Pleines I, Lebois M, et al. BCL-2 is dispensable for thrombopoiesis and platelet survival. Cell Death Dis. 2015 Apr 16;6:e1721. PMID: 25880088.

Khaw SL, Mérino D, Anderson MA, et al. Both leukaemic and normal peripheral B lymphoid cells are highly sensitive to the selective pharmacological inhibition of prosurvival Bcl-2 with ABT-199. Leukemia. 2014 Jan 9. [Epub ahead of print]. PMID: 24402163.

Balakrishnan K, Gandhi V. Bcl-2 antagonists: a proof of concept for CLL therapy. Invest New Drugs. 2013 Oct;31(5):1384-94. PMID: 23907405.

Rudin CM, Hann CL, Garon EB, et al. Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res. 2012 Jun 1;18(11):3163-9. PMID: 22496272.

Chen J, Jin S, Abraham V, et al. The Bcl-2/Bcl-X(L)/Bcl-w inhibitor, navitoclax, enhances the activity of chemotherapeutic agents in vitro and in vivo. Mol Cancer Ther. 2011 Dec;10(12):2340-9. PMID: 21914853.